Epperly Melissa B,
Known title: DirectorCIK: 0001807359
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Transaction History
| ROIV | ▲ Buy | Option Exercise | 17,750 | $79K | 10/1/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 16,850 | $608K | 10/1/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 900 | $33K | 10/1/2026 | View on chart |
| ROIV | ▲ Buy | Grant | 5,054 | $0 | 9/16/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 4,338 | $172K | 9/15/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 600 | $24K | 9/15/2026 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 2,179 | $89K | 9/10/2026 | View on chart |
| ROIV | ▲ Buy | Grant | 543 | $0 | 7/17/2026 | View on chart |
| ROIV | ▲ Buy | Option Exercise | 17,750 | $79K | 6/29/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 15,002 | $515K | 6/29/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 2,748 | $95K | 6/29/2026 | View on chart |
| ROIV | ▲ Buy | Grant | 670 | $0 | 4/17/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 41,861 | $1.2M | 3/16/2026 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 54 | $1K | 1/20/2026 | View on chart |
| ROIV | ▲ Buy | Grant | 815 | $0 | 1/20/2026 | View on chart |
| ROIV | ▲ Buy | Grant | 1,056 | $0 | 10/20/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 14,524 | $0 | 9/10/2025 | View on chart |
| ROIV | ▼ Sell | Other | 1,661 | $23K | 9/10/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 1,609 | $0 | 7/17/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 1,847 | $0 | 4/17/2025 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 180 | $2K | 1/23/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 1,672 | $0 | 1/23/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 1,613 | $0 | 10/21/2024 | View on chart |
| ROIV | ▼ Sell | Other | 4,245 | $51K | 9/12/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 16,406 | $0 | 9/10/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 1,702 | $0 | 7/23/2024 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 123 | $1K | 4/24/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 1,146 | $0 | 4/24/2024 | View on chart |
| ZNTL | ▼ Sell | Open Market | 2,573 | $29K | 2/12/2024 | View on chart |
| ZNTL | ▼ Sell | Open Market | 8,669 | $100K | 2/2/2024 | View on chart |
| ZNTL | ▲ Buy | Grant | 75,000 | $0 | 2/1/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 1,207 | $0 | 1/19/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 1,226 | $0 | 10/16/2023 | View on chart |
| ZNTL | ▼ Sell | Open Market | 4,594 | $89K | 10/4/2023 | View on chart |
| ZNTL | ▼ Sell | Open Market | 888 | $18K | 10/4/2023 | View on chart |
| ROIV | ▲ Buy | Grant | 17,825 | $0 | 9/12/2023 | View on chart |
| ROIV | ▲ Buy | Grant | 1,280 | $0 | 7/3/2023 | View on chart |
| ZNTL | ▼ Sell | Open Market | 5,227 | $104K | 2/14/2023 | View on chart |
| ZNTL | ▼ Sell | Open Market | 2,624 | $54K | 2/13/2023 | View on chart |
| ZNTL | ▲ Buy | Grant | 101,957 | $0 | 2/1/2023 | View on chart |
| ZNTL | ▲ Buy | Grant | 50,000 | $0 | 10/3/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 4,512 | $235K | 4/4/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 353 | $19K | 4/4/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,303 | $65K | 4/4/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 2,818 | $143K | 4/4/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 8,094 | $395K | 4/4/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,211 | $59K | 2/23/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 702 | $35K | 2/23/2022 | View on chart |
| ZNTL | ▲ Buy | Grant | 16,405 | $0 | 2/10/2022 | View on chart |
| ZNTL | ▼ Sell | Tax Withholding | 17,080 | $1.1M | 10/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst
Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.